Comparison of Cobimetinib versus Combination of Dasatinib and Quercetin in Relieving Inflammatory Chondrocyte Senescence

• Cobimetinib effectively alleviates IL-1β-induced inflammatory senescence in chondrocytes by inhibiting the MEK-ERK1/2 pathway. • Cobimetinib shows comparable anti-senescence effects to the dasatinib and quercetin combination, with superior potential in promoting matrix synthesis and inhibiting degradation. • Both treatments downregulate senescence markers (P16, P21, P53) and reduce SASP factor expression, restoring COL2A1 and suppressing MMP13/MMP3. • Cobimetinib may serve as a promising therapeutic agent for osteoarthritis by targeting cellular senescence.